Fierce Biotech

Apogee bags $1.3B Blackstone royalty funding deal to push eczema challenger into phase 3

Apogee Therapeutics has secured a promise of up to $1.3 billion in financing from Blackstone Life Sciences (BXLS) as the ...
Fierce Biotech

FDA delays ruling on AstraZeneca’s breast cancer drug after negative adcomm vote

The FDA has delayed a decision on the approval of AstraZeneca’s camizestrant, deferring its ruling to review analyses filed ...
Fierce Biotech

Kardigan itching for IPO to fund late-stage cardiovascular pipeline

Kardigan may have only launched last year, but it seems the cardiovascular-focused biotech is already eyeing the public markets. | Kardigan may have only launched last year, but it seems the ...
Fierce Biotech

As calls for COINS Act expansion grow, will new rules sweep up China biotech licensing?

As large biopharma companies have increasingly turned to China for novel biotech innovation, political calls in the U.S. to ...
Fierce Biotech

Olympus pushes deeper into oncology with $270M BioProtect deal

Olympus has signed a definitive agreement to acquire BioProtect for $270 million, adding biodegradable balloon spacer ...